Your browser doesn't support javascript.
A boost with SARS-CoV-2 BNT162b2 mRNA vaccine elicits strong humoral responses independently of the interval between the first two doses.
Tauzin, Alexandra; Gong, Shang Yu; Chatterjee, Debashree; Ding, Shilei; Painter, Mark M; Goel, Rishi R; Beaudoin-Bussières, Guillaume; Marchitto, Lorie; Boutin, Marianne; Laumaea, Annemarie; Okeny, James; Gendron-Lepage, Gabrielle; Bourassa, Catherine; Medjahed, Halima; Goyette, Guillaume; Williams, Justine C; Bo, Yuxia; Gokool, Laurie; Morrisseau, Chantal; Arlotto, Pascale; Bazin, Renée; Fafard, Judith; Tremblay, Cécile; Kaufmann, Daniel E; De Serres, Gaston; Richard, Jonathan; Côté, Marceline; Duerr, Ralf; Martel-Laferrière, Valérie; Greenplate, Allison R; Wherry, E John; Finzi, Andrés.
  • Tauzin A; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Gong SY; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada.
  • Chatterjee D; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Ding S; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Painter MM; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylv
  • Goel RR; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Beaudoin-Bussières G; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Marchitto L; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Boutin M; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Laumaea A; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Okeny J; Department of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
  • Gendron-Lepage G; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Bourassa C; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Medjahed H; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Goyette G; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Williams JC; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Bo Y; Department of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
  • Gokool L; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Morrisseau C; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Arlotto P; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada.
  • Bazin R; Héma-Québec, Affaires Médicales et Innovation, Quebec, QC G1V 5C3, Canada.
  • Fafard J; Laboratoire de Santé Publique du Québec, Institut National de Santé Publique du Québec, Sainte-Anne-de-Bellevue, QC H9X 3R5, Canada.
  • Tremblay C; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Kaufmann DE; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Médecine, Université de Montréal, Montreal, QC H3T 1J4, Canada.
  • De Serres G; Institut National de Santé Publique du Québec, Quebec, QC H2P 1E2, Canada.
  • Richard J; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Côté M; Department of Biochemistry, Microbiology and Immunology, and Center for Infection, Immunity, and Inflammation, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
  • Duerr R; Department of Microbiology, New York University School of Medicine, New York, NY 10016, USA.
  • Martel-Laferrière V; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada.
  • Greenplate AR; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA.
  • Wherry EJ; Institute for Immunology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Immune Health, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA; Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylv
  • Finzi A; Centre de Recherche du CHUM, Montreal, QC H2X 0A9, Canada; Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montreal, QC H2X 0A9, Canada; Department of Microbiology and Immunology, McGill University, Montreal, QC H3A 2B4, Canada. Electronic address: andres.finzi@um
Cell Rep ; 41(4): 111554, 2022 10 25.
Article in English | MEDLINE | ID: covidwho-2104502
ABSTRACT
Due to the recrudescence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections worldwide, mainly caused by the Omicron variant of concern (VOC) and its sub-lineages, several jurisdictions are administering an mRNA vaccine boost. Here, we analyze humoral responses induced after the second and third doses of an mRNA vaccine in naive and previously infected donors who received their second dose with an extended 16-week interval. We observe that the extended interval elicits robust humoral responses against VOCs, but this response is significantly diminished 4 months after the second dose. Administering a boost to these individuals brings back the humoral responses to the same levels obtained after the extended second dose. Interestingly, we observe that administering a boost to individuals that initially received a short 3- to 4-week regimen elicits humoral responses similar to those observed in the long interval regimen. Nevertheless, humoral responses elicited by the boost in naive individuals do not reach those present in previously infected vaccinated individuals.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Rep Year: 2022 Document Type: Article Affiliation country: J.celrep.2022.111554

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Topics: Vaccines / Variants Limits: Humans Language: English Journal: Cell Rep Year: 2022 Document Type: Article Affiliation country: J.celrep.2022.111554